Delequamine (INNTooltip International Nonproprietary Name; developmental code names RS-15385, RS-15385-197) is a potent and selective α2-adrenergic receptor antagonist which was under development for the treatment of erectile dysfunction and major depressive disorder but was never marketed.[1][2][3][4]

It is structurally related to the naturally occurring α2-adrenergic receptor antagonist yohimbine but has greater selectivity in comparison.[3][4] The drug has been found to affect sexual function and sleep in humans.[4]

Delequamine reached phase 3 clinical trials prior to the discontinuation of its development.[1] The drug was under development in the 1990s and its development was discontinued by 1999.[1] It was first described in the scientific literature by 1990.[5]

References

  1. ^ a b c "Delequamine". AdisInsight. Springer Nature Switzerland AG. 22 September 1999. Retrieved 21 October 2024.
  2. ^ Ganellin CR, Triggle DJ (1996). Dictionary of Pharmacological Agents. Taylor & Francis. ISBN 978-0-412-46630-4. Retrieved 21 October 2024.
  3. ^ a b Maw GN (1999). "Pharmacological Therapy for the Treatment of Erectile Dysfunction". In Greenlee W, Hagmann WK, Plattner JJ, Robertson D, Trainor GL, Wong WW, Doherty AM (eds.). Annual Reports in Medicinal Chemistry. Annual Reports in Medicinal Chemistry. Vol. 34. Academic Press. p. 78. ISBN 978-0-08-058378-5. Retrieved 21 October 2024.
  4. ^ a b c Bancroft J (March 2000). "Effects of alpha-2 blockade on sexual response: experimental studies with Delequamine (RS15385)". International Journal of Impotence Research. 12 (S1): S64 – S69. doi:10.1038/sj.ijir.3900507. PMID 10849567.
  5. ^ Clark RD, Spedding M, MacFarlane CB (1990). "RS-15385-197, a potent andselective alpha2-adrenoceptor antagonist". British Journal of Pharmacology. 99: 123P.
Allikas: https://en.wikipedia.org/wiki/Delequamine
No tags for this post.